IP Library Granted Patent US 7,381,801
Granted Patent B2
US 7,381,801 · App. 10/365,123 · Granted Jun 3, 2008

Chimerized GM-CSF antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,381,801
App. No.
10/365,123
Granted
Jun 3, 2008
Kind
B2
Abstract

Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed.

Claims (3)

1. A chimerized GM-CSF specific antibody consisting of a light chain, the amino acid sequence of which consists of, in N terminal to C terminal order, the amino acids encoded by nucleotides 1357-1752 of SEQ ID NO: 35, followed by the amino acid sequence encoded by nucleotides 1886-2203 of SEQ ID NO: 35, and a heavy chain, the amino acid sequence of which consists of, in N terminal to C terminal order, the amino acids encoded by nuoleotides 1357-1764 of SEQ ID NO: 36, followed by the amino acid sequence encoded by nucleotides 1839-2825 of SEQ ID NO: 36, wherein said chiinerized GM-CSF specific antibody inhibits TF-1 cell growth by more than 50% at a concentration of 10 μg/ml in the presence of 0.5 ng/ml recombinant human GM-CSF.

2. A chimerized, GM-CSF specific antibody comprising a chimeric light chain encoded by an isolated nucleic acid molecule, the amino acid sequence of which consists of, in N terminal to C-terminal order, the amino acids encoded by nucleotides 1357-1742 of SEQ ID NO: 35 followed by the amino acid sequence encoded by nucleotides 1886-2203 of SEQ ID NO: 35.

3. A chimerized, GM-CSF specific antibody comprising a chimeric heavy chain encoded by an isolated nucleic acid molecule, the nucleotide sequence of which consist of in N-terminal to C-terminal order, the amino acids encoded by nucleotides 1357-1764 of SEQ ID NO: 36, followed by the amino acid sequence encoded by nucleotides 1839-2825 of SEQ ID NO: 36.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045788/0148 →
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045855/0533 →
SECURITY INTEREST Recorded Dec 22, 2016
From: KALOBIOS PHARAMECUTICALS, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 041181/0605 →
SECURITY INTEREST Recorded May 23, 2016
From: KALOBIOS PHARMACEUTICALS, INC.
To: BLACK HORSE CAPITAL, LP
Reel/Frame 038788/0266 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNOR, PREVIOUSLY RECORDED ON REEL 014069 FRAME 0546. Recorded Jan 12, 2004
From: RENNER, CHRISTOPH; BURGESS, ANTONY; SCOTT, ANDREW
To: LUDWIG INSTITUTE OF CANCER RESEARCH
Reel/Frame 014896/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2003
From: RENNER, CHRISTOPHER; BURGESS, ANTONY; SCOTT, ANDREW
To: LUDWIG INSTITUTE FOR CANCER RESEARCH
Reel/Frame 014069/0546 →